Skip to main content

Day: February 24, 2026

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company’s biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmune diseases. Athos has developed AthosOmics.AI, a proprietary AI-driven drug development platform that resulted in the discovery of...

Continue reading

Rick Jordan CEO of Frequency Holdings (OTC: FRQN) To Join Tim Pool’s “Timcast IRL” Podcast

Amid DHS Shutdown, TSA PreCheck Whiplash, High‑Stakes Spending Fight, and National Security Unrest Chicago, IL, Feb. 24, 2026 (GLOBE NEWSWIRE) — Rick Jordan, CEO of Frequency Holdings, Inc. (OTC: FRQN), host of the top podcast Frequency with Rick Jordan, and creator of the COVID‑era documentary Liberty Lockdown, will appear this week on Tim Pool’s flagship show Timcast IRL, one of YouTube’s most‑watched political talk formats. The episode will air live on Thursday February 26th at 8pm ET, and the conversation will dive into government overreach, the Department of Homeland Security shutdown, and how political games in Washington are colliding with AI, cybersecurity, and everyday American life.Rick Jordan Host of the Top Podcast FREQUENCY with Rick Jordan and CEO of Frequency Holdings (OTC: FRQN) Hosted by journalist and commentator...

Continue reading

Dynacor Group Announces March 2026 Dividend

MONTREAL, Feb. 24, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announced today that its Board of Directors has approved a monthly dividend of C$0.01333 per common share (C$0.16 annually) for March 2026. This will be payable on March 17, 2026, to shareholders of record as of the close of business on March 9, 2026. The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes. The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board. About Dynacor Dynacor Group is an industrial ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment...

Continue reading

Abits Group Inc Announces Closing of $2.1 Million Registered Direct Offering

HONG KONG, Feb. 24, 2026 (GLOBE NEWSWIRE) — Abits Group Inc (NASDAQ: ABTS) (the “Company”), a new generation digital center with inhouse bitcoin mining operations, today announced the closing of the previously announced registered direct offering with institutional investors of approximately $2.1 million of Ordinary Shares and pre-funded warrants at a price of $2.65 per Ordinary Share. The entire transaction was priced at the market under Nasdaq rules. The offering consisted of the sale of 792,452 Ordinary Shares or Pre-Funded Warrants. The price per Ordinary Share was $2.65 (or $2.64999 for each Pre-Funded Warrant, which is equal to the offering price per Ordinary Share sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any...

Continue reading

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENERATIVE DISEASES Paris, February 24, 2026, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS). The key characteristics of this newly identified biomarker...

Continue reading

[Press Release] 2025 results in line with guidance – Launch of Horizons strategic plan

2025 results in line with guidanceLaunch of Horizons strategic plan Paris, February 24th, 2026 – Ipsos, one of the world’s leading market research and opinion polling companies, today announces its full-year 2025 results. Revenue, organic growth and operating margin rate, communicated on a preliminary basis at the Investor Day on 22 January, are confirmed.Revenue: €2,525 millionTotal growth: +3.4% Organic growth: +0.6%Operating margin: €309 millionOperating margin rate: 12.3% Operating margin rate at constant scope*: 12.8%*Excluding temporarily dilutive effect related to The BVA Family and infas acquisitions Ipsos recorded revenue of €2,524.7 million in 2025, up 3.4%, including 0.6% organic growth, a 5.8% scope effect mainly related to the acquisitions of The BVA Family and infas, and a negative 3.0% foreign...

Continue reading

BIC: FULL YEAR 2025 RESULTS

Clichy, France – February 24, 2026 FULL YEAR 2025 RESULTS Challenging year in 2025 with an improved momentum in the second half. Resilient free cash flow generation Renewed governance and executive leadership team to lead BIC’s next phase of growth Initial strategic actions launched in H2 2025 to streamline the portfolio FY net sales of €2,090m, -0.9% at constant currency (-4.7% on a comparative basis1), in a particularly challenging US environment. Q4 net sales of €495m, +1.1% at constant currency (-2.3% on a comparative basis1) with robust performance of Tangle Teezer as well as strong growth in Brazil and Middle East and Africa. 2025 adjusted EBIT of €283m (vs. €343m in 2024), adjusted EBIT margin of 13.6% reflecting a decline in gross profit margin, partially offset by some cost control. 2025 adjusted EPS at €4.74 (vs. €6.15 in 2024). Resilient...

Continue reading

New Toll Brothers Community Now Open in Magnolia, Texas

Toll Brothers at Wildtree offers luxury homes with access to premier amenities MAGNOLIA, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced Toll Brothers at Wildtree, a new Houston-area community of one- and two-story homes, is now open in Magnolia, Texas. Located in Montgomery County, this exceptional community features modern home designs on expansive 60-foot-wide home sites. The Toll Brothers Sales Center is now open at 4919 Pinestraw Valley Way in Magnolia.Homes at Toll Brothers at Wildtree range from approximately 3,078 to over 3,600 square feet and offer 4 to 5 bedrooms and 3 to 4.5 baths. With unique architectural details including cathedral ceilings and spiral staircases, these homes provide a perfect blend of style and functionality. Pricing...

Continue reading

NOTICE TO THE HOLDERS of CH1108679908, Series 6800, Open ended Valour Mantra (OM) SEK (the “Certificates”) issued by Valour Inc., LEI: 984500RAH11EE88V4014 (the “Issuer”)

OM-Mantra Token Swap, Redenomination and Rebranding – Transformation Event ZUG, Switzerland, Feb. 24, 2026 (GLOBE NEWSWIRE) — Binance has announced that the Digital Asset under the Certificates will be subject to a MANTRA (OM) token swap, redenomination and rebranding to MANTRA (MANTRA):OM tokens will assume the ticker of MANTRA tokens on Binance; All OM tokens will be swapped to MANTRA at a ratio of 1 OM = 4 MANTRA though a non-dilutive split; Implementation is currently expected to take effect on 2 March 2026; and Separately, a trading halt at Spotlight regarding the Certificates is expected to be imposed on 2 March and 3 March 2026 to ensure orderly fair and market conditions.Further information regarding the token swap, redenomination and rebranding is available at: https://www.binance.com/en/support/announcement/detail/4d13052b4be943f5b155cb9150ca902c?utm_source=new_share&ref=CPA_00Q01Y04QJ The...

Continue reading

JIADE LIMITED Signs Non-Binding MOU to Explore Korea–U.S. Technology Investments

Chengdu, China, Feb. 24, 2026 (GLOBE NEWSWIRE) — JIADE LIMITED (Nasdaq: JDZG) (“JIADE” or the “Company”), a provider of one-stop comprehensive education support services for adult education institutions through its subsidiaries in the People’s Republic of China, today announced that it entered into a non-binding strategic cooperation memorandum of understanding (“MOU”) on February 24, 2026 with Chinalink Education Group (“Chinalink”), a South Korea–based education brand specializing in artificial intelligence (AI)-empowered educational and cultural exchange programs, to explore cross-border investment opportunities in high-growth technology sectors. This initiative is intended to build upon the Company’s previously announced cross-border cooperation framework with Chinalink and reflects JIADE’s continued efforts to expand its international...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.